Cell Therapy Bioreactors Market Global Report 2026

The cell therapy bioreactors market size has grown rapidly in recent years. It will grow from $1.24 billion in 2025 to $1.44 billion in 2026 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to increasing demand for cell-based therapeutic applications, growing investments in regenerative medicine, wider adoption of automated cell culture technologies, expansion of stem cell research activities, and rising requirements for scalable cell production capabilities.

The cell therapy bioreactors market size is expected to see rapid growth in the next few years. It will grow to $2.61 billion in 2030 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to increasing utilization of cell therapy bioreactors in manufacturing processes, rising investments in advanced bioprocessing technologies, greater emphasis on process optimization and quality assurance, expansion of clinical studies involving cell therapies, and growing demand for personalized medicine applications. Major trends in the forecast period include advancements in automated cell culture technologies, continued innovation in bioreactor designs to improve scalability, development of advanced stem cell expansion platforms, increasing research and development in process monitoring and control systems, and emergence of integrated solutions for cell therapy manufacturing.

The growing demand for gene therapies is expected to drive the growth of the cell therapy bioreactors market going forward. Gene therapy refers to a medical technique that involves modifying or replacing defective genes to treat or prevent diseases. The rising demand for gene therapy is attributed to advancements in genetic sequencing and diagnostics, which enable the precise identification of disease-causing genes for targeted treatment. Cell therapy bioreactors accelerate gene therapies by providing optimized environments for the growth, modification, and expansion of therapeutic cells. They support treatment development and scalability by ensuring consistent cell quality, enhancing efficiency, and enabling faster production of personalized gene-based therapies. For instance, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved 6 gene therapy products in 2023, compared with 5 approvals in 2022. Therefore, the growing demand for gene therapies is driving the growth of the cell therapy bioreactors market.

The increasing prevalence of chronic diseases is expected to drive the growth of the cell therapy bioreactors market going forward. Chronic and rare diseases refer to long-term health conditions and uncommon disorders that often require specialized treatment approaches, including personalized and regenerative therapies. The prevalence of chronic diseases is increasing largely due to unhealthy lifestyles, including poor diet, physical inactivity, and smoking, which increase the risk of conditions such as diabetes, heart disease, and obesity. Cell therapy bioreactors support chronic disease management by providing controlled environments for the cultivation and expansion of therapeutic cells. They improve treatment effectiveness and scalability by ensuring consistent cell quality, enabling personalized therapies, and supporting long-term patient care. For instance, in 2025, according to the International Diabetes Federation, a Belgium-based health organization, around 589 million adults aged 20-79 were living with diabetes in 2024, with the total number projected to reach 853 million by 2050. Therefore, the increasing prevalence of chronic and rare diseases is driving the growth of the cell therapy bioreactors market.

Key companies operating in the cell therapy bioreactors market are concentrating on developing advanced platforms, such as modular, multi-scale bioreactor platforms, to enhance process scalability, cell expansion efficiency, and consistency from early-stage research through commercial manufacturing. A modular multi-scale bioreactor platform refers to a flexible system that allows researchers to perform parallel small-scale experiments, optimize process conditions, and seamlessly scale up to mid- or large-scale production while maintaining consistent culture conditions and high yields. For example, in July 2024, EXO-Harvest, a Belgium-based biomanufacturing technology company, launched its advanced multi-scale bioreactor platform for the efficient manufacturing of mesenchymal stem cells and extracellular vesicles, supporting scalable adherent cell culture from discovery through industrial production. The platform includes small-scale multi-bioreactor screening capabilities as well as mid- and large-scale systems designed to accelerate development, reduce costs, and produce high-quality cultures with precise environmental control.

Major companies operating in the cell therapy bioreactors market are Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Danaher Corporation, Corning Incorporated, Lonza Group, Terumo Corporation, Sartorius AG, Eppendorf AG, Miltenyi Biotec B.V. & Co. KG, PBS Biotech Inc., Meissner Filtration Products Inc., Infors AG, Bionet Engineering & Technologies Pvt. Ltd., Wilson Wolf Manufacturing Corporation, Synthecon Incorporated, Cellexus Limited, Celartia Inc., Able Biott Inc., CelVivo ApS.

North America was the largest region in the cell therapy bioreactors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy bioreactors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cell therapy bioreactors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 1-3 business days.